For more than two decades, Partners In Health has been working to treat multidrug-resistant tuberculosis (MDR-TB) and extensively-drug resistant tuberculosis (XDR-TB) across three continents. From the slums of Lima, Peru, to the mountains of Lesotho, to the streets of Tomsk, Russia, we’ve pioneered a community-based treatment model aimed at alleviating the clinical, social, and economic factors that fuel the disease. As the global burden of MDR-TB and XDR-TB increases, PIH remains committed to building local capacity, providing long-term accompaniment, and forging partnerships with local ministries of health and other stakeholders.

For more information and resources from the Partners In Health, please visit:
http://www.pih.org/ and https://drtbnetwork.org/resources.

 

 

GUIDELINES 

TRAINING MATERIALS

 

 

PEER-REVIEWED PUBLICATIONS

 

Selected publications on DR-TB 2012-2013 from HMS/BWH/Partners In Health group

  1. Lu C, Liu Q, Sarma A, Fitzpatrick C, Falzon D, Mitnick CD. A systematic review of reported cost for smear and culture tests during multidrug-resistant tuberculosis treatment. PloS one 2013;8:e56074. (Full text)
  2. Becerra MC, Franke MF, Appleton SC, Joseph JK, Bayona J, Atwood SS, Mitnick CD. Tuberculosis in children exposed at home to multidrug-resistant tuberculosis. Pediatric Infectious Disease Journal 2013;32(2):115-9. (Full text)
  3. Dharmadhikari AS, Kabadi M, Gerety B, Hickey AJ, Fourie PB, Nardell E. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrobial Agents and Chemotherapy 2013;57:2613-9. (Abstract)
  4. Dooley KE, Obuku EA, Durakovic N, Belitsky V, Mitnick C, Nuermberger EL on behalf of the Efficacy Sub-group, RESIST-TB. World Health Organization Group 5 Drugs for the treatment of drug-resistant tuberculosis: Unclear efficacy or untapped potential? J Infect Dis 2013; 207(9):1352-8. (Full text)
  5. Franke MF, Appleton SC, Mitnick CD, et al. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clinical Infectious Diseases 2013;56:770-6. (Full text)
  6. Horsburgh CR Jr, Haxaire-Theeuwes M, Lienhardt C, Wingfield C, McNeeley D, Pyne-Mercier L, Keshavjee S, Varaine F; Research Excellence to Stop TB Resistance (RESIST-TB); Critical Path to TB Drug Regimens' Access and Appropriate Use Workgroup. Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2013 Feb;17(2):146-52. (Full text)
  7. Hwang TJ, Wares DF, Jafarov A, Jakubowiak W, Nunn P, Keshavjee S. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis [Review article]. Int J Tuberc Lung Dis. 2013 Oct;17(10):1257-66. doi: 10.5588/ijtld.12.0863. Epub 2013 Jun 3. (Abstract)
  8. Mitnick CD, Franke MF, Rich ML, et al. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLOS ONE 2013;8:e58664. (Full text)
  9. Mitnick CD, Keravec J, Cohen T. Planning for the invisible: projecting resources needed to identify and treat all patients with MDR-TB. International Journal of Tuberculosis and Lung Disease 2013;17:427-8. (Full text)
  10. Satti H, McLaughlin MM, Seung KJ. Drug-resistant tuberculosis treatment complicated by antiretroviral resistance in HIV coinfected patients: a report of six cases in Lesotho. Am J Trop Med Hyg. 2013 Jul;89(1):174-7. doi: 10.4269/ajtmh.13-0046. Epub 2013 May 13. (Abstract)
  11. Seung KJ, Becerra MC, Atwood SS, Alcántara F, Bonilla CA, Mitnick CD. Salvage therapy for multidrug-resistant tuberculosis. Clin Microbiol Infect. 2013 Jul 18. doi: 10.1111/1469-0691.12335. [Epub ahead of print] (Abstract)
  12. Seung KJ, Linton SW. The growing problem of multidrug-resistant tuberculosis in North Korea. PLOS Med. 2013 Jul;10(7):e1001486. doi: 10.1371/journal.pmed.1001486. Epub 2013 Jul 30. (Full text)
  13. Yuen CM, Tolman AW, Cohen T, Parr JB, Keshavjee S, Becerra MC. Isoniazid-resistant tuberculosis in children: a systematic review. Pediatr Infect Dis J. 2013 May;32(5):e217-26. doi: 10.1097/INF.0b013e3182865409. (Abstract)
  14. Cohen T, Manjourides J, Hedt-Gauthier B. Linking surveillance with action against drug-resistant tuberculosis. American Journal of Respiratory and Critical Care Medicine 2012;186:399-401. (Full text)
  15. Dooley KE, Mitnick CD, DeGroote AM, Obuku E, Belitsky V, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N, Nuermberger E; on behalf of the Efficacy Sub-group, RESIST-TB. Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. Clinical Infectious Diseases 2012;55:572-81. (Full text)
  16. Miller AC, Gelmanova IY, Keshavjee S, Atwood S, Yanova G, Mishustin S, Furin JJ, Shin SS. Alcohol use and the management of multidrug-resistant tuberculosis in Tomsk, Russian Federation. Int J Tuberc Lung Dis. 2012 Jul;16(7):891-6. doi: 10.5588/ijtld.11.0795. Epub 2012 Apr 9. (Full text)
  17. Keshavjee S, Gelmanova IY, Shin SS, Mishustin SP, Andreev YG, Atwood S, Furin JJ, Miller A. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome. Int J Tuberc Lung Dis. 2012 May;16(5):596-603. doi: 10.5588/ijtld.11.0591. Epub 2012 Mar 7. (Full text)
  18. Gelmanova IY, Taran DV, Mishustin SP, Golubkov AA, Solovyova AV, Keshavjee S. 'Sputnik': a programmatic approach to improve tuberculosis treatment adherence and outcome among defaulters. International Journal of Tuberculosis and Lung Disease 2011;15:1373-9. (Full text)